Drug Profile
Research programme: antibody-drug conjugates - Compugen
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Compugen
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in Israel
- 12 Dec 2013 Compugen identifies five potential targets for antibody-drug conjugate cancer therapy
- 03 Apr 2013 Early research in Cancer in Israel (unspecified route)